INS.L Regulatory News (INS)

9 February 2012

Instem plc

("Instem", or the "Company")

Director/PDMR Shareholding

Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, announces that Chief Financial Officer, Nigel Goldsmith has been granted options over 20,000 ordinary shares of 10p each ("Ordinary Shares"). These options become exercisable after a period of three years subject to market based performance criteria, pursuant to the rules of the Company's All Staff LTIP and approved by the Remuneration Committee on 7 February 2012. The exercise price of 176p represents the closing mid-market price of the Ordinary Shares as at 7 February 2012.

For further information, please contact:

About Instem plc

Instem (AIM:INS.L) is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

In March 2011 Instem acquired BioWisdom Limited, a leading provider of software solutions for extracting intelligence from R&D related healthcare data. The acquisition broadened and strengthened Instem's Centrus™ product suite, accelerating the product development roadmap.

Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Company employs over 110 people in six offices in the U.S, UK, and China; with additional resource locations in India and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software.

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/.